{"ticker": {"uuid": "76f00b03-db0c-498b-a35e-af21ceacae26", "symbol": "RNAC", "name": "Cartesian Therapeutics Inc.", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Enterprise value to EBITDA forward of Cartesian Therapeutics, Inc. \u2013 NASDAQ:RNAC", "summary": "This article displays financial data for Cartesian Therapeutics, Inc. (NASDAQ: RNAC), focusing on its enterprise value to EBITDA forward metric. The content appears to be a financial data snippet from TradingView, indicating no current trades and providing links to various financ", "url": "https://www.tradingview.com/symbols/NASDAQ-RNAC/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-07-14T22:43:58", "published_display": "14 Jul 2026 22:43", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Cartesian Therapeutics Inc (RNAC)", "summary": "This article provides key financial data for Cartesian Therapeutics Inc (RNAC), a biotechnology and medical research company listed on the Nasdaq Stock Market. It summarizes its stock price, daily and 52-week ranges, market capitalization, outstanding shares, and earnings per sha", "url": "https://www.msn.com/en-ph/money/stockdetails/rnac-us-stock/fi-a22roc?ocid=winp2fpent", "source_name": "MSN", "published_at": "2026-07-12T22:40:49", "published_display": "12 Jul 2026 22:40", "sentiment": "negative", "sentiment_pct": 39, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kyverna Therapeutics Sinks 13%: Here\u2019s Why", "summary": "", "url": "https://finance.yahoo.com/m/57b629c0-9b57-300d-bab5-69e9c31cc364/kyverna-therapeutics-sinks.html", "source_name": "24/7 Wall St.", "published_at": "2026-07-10T19:59:59+00:00", "published_display": "10 Jul 2026 19:59", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cartesian Therapeutics : RNAC", "summary": "", "url": "https://news.google.com/rss/articles/CBMiTkFVX3lxTE9xSTBIdDZCV21zaHJwRVE5Q0xkS3dEcUY1R2NocGsyN1JjRF8zazMySW9iams2TktuLUtSTWUxMmZFTGR2Z1gzNnBudm5Bdw?oc=5", "source_name": "24/7 Wall St.", "published_at": "2026-07-10T19:59:59+00:00", "published_display": "10 Jul 2026 19:59", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cartesian Therapeutics Inc. : RNAC", "summary": "This article provides details on Cartesian Therapeutics Inc. (RNAC), a clinical-stage biopharmaceutical company focusing on nanoparticle immunomodulatory drugs. It lists the company's stock data, including its NASDAQ exchange, USD currency, and its classification within the healt", "url": "https://247wallst.com/companies/rnac/", "source_name": "24/7 Wall St.", "published_at": "2026-07-10T20:41:03", "published_display": "10 Jul 2026 20:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "macro", "event_label": "Macro sensitivity", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Emerging Therapies Transforming the Myasthenia Gravis Market by DelveInsight | Sanofi, Cartesian Therapeutics, Takeda, UCB Biopharma, Roche, Janssen R&D, Immunovant Sciences GmbH, Argenx-Halozyme", "summary": "The Myasthenia Gravis market is projected to grow significantly from approximately USD 6 billion in 2025 to nearly USD 16 billion by 2036, driven by new therapies and increased awareness. Recent FDA approvals for treatments like Vyvgart and UPLIZNA have expanded options for patie", "url": "https://www.barchart.com/story/news/3203735/emerging-therapies-transforming-the-myasthenia-gravis-market-by-delveinsight-sanofi-cartesian-therapeutics-takeda-ucb-biopharma-roche-janssen-rd-immunovant-sciences-gmbh-argenxhalozyme", "source_name": "Barchart.com", "published_at": "2026-07-10T08:40:08", "published_display": "10 Jul 2026 08:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wedbush Initiates Coverage of Cartesian Therapeutics (RNAC) with Outperform Recommendation", "summary": "Wedbush has initiated coverage of Cartesian Therapeutics (RNAC) with an Outperform recommendation. This indicates a positive outlook from the analyst firm regarding the company's stock performance. Investors will likely watch for further developments and market reactions to this ", "url": "https://www.msn.com/en-us/technology/biotechnology/wedbush-initiates-coverage-of-cartesian-therapeutics-rnac-with-outperform-recommendation/ar-AA1IhBOf?apiversion=v2&domshim=1&noservercache=1&noservertelemetry=1&batchservertelemetry=1&renderwebcomponents=1&wcseo=1", "source_name": "MSN", "published_at": "2026-07-04T20:09:26", "published_display": "04 Jul 2026 20:09", "sentiment": "positive", "sentiment_pct": 75, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cartesian Therapeutics Announces New Employment Inducement Grants", "summary": "Cartesian Therapeutics, Inc. has granted inducement awards to eight new employees, issuing options to purchase a total of 238,700 shares of common stock at an exercise price of $10.18. These options, vesting over four years, were granted on July 1, 2026, under the Company\u2019s Amend", "url": "https://www.manilatimes.net/2026/07/02/tmt-newswire/globenewswire/cartesian-therapeutics-announces-new-employment-inducement-grants/2377429", "source_name": "The Manila Times", "published_at": "2026-07-03T06:38:49", "published_display": "03 Jul 2026 06:38", "sentiment": "positive", "sentiment_pct": 64, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cartesian offers 8 new hires stock options worth 238,700 shares", "summary": "Cartesian Therapeutics (NASDAQ: RNAC) granted inducement stock options for 238,700 common shares to eight new employees, effective July 1, 2026. The options have an exercise price of $10.18 and will vest 25% on July 1, 2027, with the remainder vesting monthly until July 1, 2030. ", "url": "https://www.stocktitan.net/news/RNAC/cartesian-therapeutics-announces-new-employment-inducement-gfg7sovh36xa.html", "source_name": "Stock Titan", "published_at": "2026-07-02T10:41:06", "published_display": "02 Jul 2026 10:41", "sentiment": "positive", "sentiment_pct": 63, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RNAC - Cartesian Therapeutics Inc Latest SEC Filings", "summary": "This article provides the latest SEC filing information for Cartesian Therapeutics Inc. (RNAC), including its last closing price, financial overview, stock performance metrics, insider and institutional ownership, and profitability ratios. It details various financial statistics ", "url": "https://finviz.com/stock?t=RNAC&b=2&p=d&ty=lf", "source_name": "Finviz", "published_at": "2026-06-30T05:10:00", "published_display": "30 Jun 2026 05:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Cartesian Therapeutics, Inc. \u2013 NASDAQ:RNAC", "summary": "This article provides the enterprise value to EBIT forward for Cartesian Therapeutics, Inc. (NASDAQ: RNAC). It appears to be a financial data snippet from TradingView, focusing on key financial metrics for the biotechnology company. The content primarily lists navigation and site", "url": "https://www.tradingview.com/symbols/NASDAQ-RNAC/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T06:40:41", "published_display": "28 Jun 2026 06:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Cartesian Therapeutics, Inc. \u2013 GETTEX:1S70", "summary": "The article provides financial information for Cartesian Therapeutics, Inc. (GETTEX:1S70), specifically focusing on its \"Price to book forward\" metric. It appears to be a financial data page from TradingView, showing that the market is closed with no trades.", "url": "https://www.tradingview.com/symbols/GETTEX-1S70/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T15:10:19", "published_display": "26 Jun 2026 15:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Cartesian Therapeutics, Inc. \u2013 NASDAQ:RNAC", "summary": "This article provides financial information for Cartesian Therapeutics, Inc. (NASDAQ: RNAC) focusing on its price-to-earnings forward metric. It appears to be a stub or an incomplete data listing from a financial platform like TradingView, with placeholders for specific values. T", "url": "https://www.tradingview.com/symbols/NASDAQ-RNAC/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T13:41:00", "published_display": "26 Jun 2026 13:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cartesian Therapeutics, Inc. Actuals & Estimates (NASDAQ:RNAC)", "summary": "This article provides an overview of Cartesian Therapeutics, Inc. (NASDAQ: RNAC) stock, including its current price, historical highs and lows, market capitalization, and analyst forecasts. It details financial actuals and estimates for income, balance, and cash flow statements, ", "url": "https://www.tradingview.com/symbols/NASDAQ-RNAC/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T08:09:58", "published_display": "26 Jun 2026 08:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cartesian Therapeutics, Inc. Actuals & Estimates (BOATS:RNAC)", "summary": "This article provides an overview of Cartesian Therapeutics, Inc. (RNAC) stock, including its financial actuals and estimates as traded on BOATS exchange. It covers analyst forecasts, historical price data, upcoming earnings reports, and key financial metrics like revenue, net in", "url": "https://www.tradingview.com/symbols/BOATS-RNAC/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T06:41:00", "published_display": "26 Jun 2026 06:41", "sentiment": "negative", "sentiment_pct": 40, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Cartesian Therapeutics, Inc. \u2013 GETTEX:1S70", "summary": "This page provides financial information for Cartesian Therapeutics, Inc. under the ticker GETTEX:1S70, specifically focusing on its price-to-sales forward metric. The data is explicitly noted as \"Made by humans\" and the market status is closed with no trades.", "url": "https://www.tradingview.com/symbols/GETTEX-1S70/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-25T22:40:52", "published_display": "25 Jun 2026 22:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cartesian Therapeutics Inc (RNAC) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of Cartesian Therapeutics Inc (RNAC), detailing its current price momentum, support and resistance levels, and indicator readings. It highlights that the stock is trading between resistance at $12.06 and support at $7.03, suitable for ra", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-rnac/technical", "source_name": "TradingKey", "published_at": "2026-06-24T10:12:25", "published_display": "24 Jun 2026 10:12", "sentiment": "positive", "sentiment_pct": 64, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RNAC Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a stock forecast for Cartesian Therapeutics, Inc. (RNAC) including analyst price targets, current stock performance, and historical price data. It also details the company's financials, future earnings expectations, and market capitalization, offering insigh", "url": "https://www.tradingview.com/symbols/NASDAQ-RNAC/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-24T08:10:11", "published_display": "24 Jun 2026 08:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cartesian Therapeutics (Nasdaq:RNAC) - Stock Analysis", "summary": "Cartesian Therapeutics (Nasdaq:RNAC) is a clinical-stage biotechnology company developing mRNA cell therapies for autoimmune diseases. The stock is currently trading significantly below its estimated fair value, but faces risks including negative shareholder equity, volatile shar", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rnac/cartesian-therapeutics", "source_name": "Simply Wall Street", "published_at": "2026-06-22T02:10:36", "published_display": "22 Jun 2026 02:10", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cartesian Therapeutics Shareholders Back Directors and Governance Measures", "summary": "Cartesian Therapeutics shareholders demonstrated strong support for the company's leadership and governance, electing three Class I directors and approving executive compensation. They also ratified Ernst & Young LLP as their independent public accounting firm for 2026, indicatin", "url": "https://www.theglobeandmail.com/investing/markets/stocks/RNAC/pressreleases/2546685/cartesian-therapeutics-shareholders-back-directors-and-governance-measures/", "source_name": "The Globe and Mail", "published_at": "2026-06-19T00:39:37", "published_display": "19 Jun 2026 00:39", "sentiment": "negative", "sentiment_pct": 40, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Shareholders of Cartesian Therapeutics (NASDAQ: RNAC) back board, pay and auditor", "summary": "Cartesian Therapeutics (NASDAQ: RNAC) shareholders held their 2026 Annual Meeting, with an 82.42% turnout. They elected three Class I directors to serve until the 2029 Annual Meeting, approved executive compensation on an advisory basis, and ratified Ernst & Young LLP as their in", "url": "https://www.stocktitan.net/sec-filings/RNAC/8-k-cartesian-therapeutics-inc-reports-material-event-c1847f5af63b.html", "source_name": "Stock Titan", "published_at": "2026-06-17T20:10:42", "published_display": "17 Jun 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cartesian Therapeutics Inc (RNAC) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article from TradingKey reports on Cartesian Therapeutics Inc (RNAC)'s stock performance, showing a 5% gain. However, it notes that relevant data regarding the company's revenue breakdown by business segments and regions has not yet been disclosed. The page primarily serves ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-rnac/revenue", "source_name": "TradingKey", "published_at": "2026-06-17T09:10:18", "published_display": "17 Jun 2026 09:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cartesian Therapeutics Inc (RNAC) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "This article provides an earnings forecast for Cartesian Therapeutics Inc (RNAC), detailing its current earnings forecast score, analyst ratings, and price targets. It highlights that the company's expected revenue for the next quarter is $134.75K and the average analyst price ta", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-rnac/earnings", "source_name": "TradingKey", "published_at": "2026-06-16T23:40:33", "published_display": "16 Jun 2026 23:40", "sentiment": "positive", "sentiment_pct": 63, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cartesian Therapeutics Inc PE Ratio (TTM) & PE Ratio (TTM) Charts - RNAC", "summary": "This article from GuruFocus.com provides a detailed financial overview of Cartesian Therapeutics Inc (RNAC), focusing on its Price-to-Earnings (PE) Ratio (TTM). It highlights that the company is currently operating at a loss, thus its TTM PE ratio is listed as \"At Loss.\" The arti", "url": "https://www.gurufocus.com/stock/US059K/data/pe-ratio", "source_name": "GuruFocus", "published_at": "2026-06-15T23:08:50", "published_display": "15 Jun 2026 23:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cartesian Therapeutics Announces In Vivo CAR-T Licensing Alliance", "summary": "Cartesian Therapeutics has formed a strategic licensing alliance with WestGene Biopharma to develop in vivo CAR-T therapies for autoimmune diseases. This collaboration will combine Cartesian\u2019s mRNA payloads with WestGene\u2019s lipid nanoparticle delivery platform, aiming to eliminate", "url": "https://www.theglobeandmail.com/investing/markets/stocks/RNAC/pressreleases/2397566/cartesian-therapeutics-announces-in-vivo-car-t-licensing-alliance/", "source_name": "The Globe and Mail", "published_at": "2026-06-13T12:10:48", "published_display": "13 Jun 2026 12:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cartesian Therapeutics Announces New Employment Inducement Grant", "summary": "Cartesian Therapeutics, Inc. (NASDAQ: RNAC) announced the granting of an inducement award to a new employee on June 8, 2026. The award includes an option to purchase 6,100 shares of common stock at an exercise price of $5.86, vesting over four years. This grant aligns with Nasdaq", "url": "https://www.globenewswire.com/news-release/2026/06/12/3311308/0/en/cartesian-therapeutics-announces-new-employment-inducement-grant.html", "source_name": "GlobeNewswire", "published_at": "2026-06-13T09:41:10", "published_display": "13 Jun 2026 09:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "New hire at Cartesian gets 6,100 stock options vesting to 2030", "summary": "Cartesian Therapeutics (NASDAQ: RNAC) has granted a new employee an inducement stock option for 6,100 shares at an exercise price of $5.86. The option vests through June 8, 2030, with 25% vesting after one year and the remainder in monthly installments, and has a ten-year term. T", "url": "https://www.stocktitan.net/news/RNAC/cartesian-therapeutics-announces-new-employment-inducement-exmhp6osmm4q.html", "source_name": "Stock Titan", "published_at": "2026-06-12T20:09:40", "published_display": "12 Jun 2026 20:09", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cartesian Therapeutics Signs Licensing Agreement With WestGene to Develop Therapies for Autoimmune Diseases", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/cartesian-therapeutics-signs-licensing-agreement-124226099.html", "source_name": "MT Newswires", "published_at": "2026-06-09T12:42:26+00:00", "published_display": "09 Jun 2026 12:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cartesian Therapeutics stock jumps on WestGene partnership deal By Investing.com", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxPNHY3SERkMHBsRk9wTTFnQlpnZHpqeE9FUVZoVVJQaUp2MFA5NWVxT2FZcWc5YzZqNHJwNFRZWXJFVm4xX1ZSOXBrNV9PckE4aFNiQjlZTWRPRnd4WllyT1JsanIzQm9TTnF2dkM1MUM0b3ozOWlFSXp0M1plZkFEM2l3NEx4ZVBVR0hPRVJtdDI5dHpOdXFYR081MktRZFlYUjFrU25mOVZwYUVpVHpnMFBhWnRjdEEzMEJ6N1NXVm9aZw?oc=5", "source_name": "Investing.com Nigeria", "published_at": "2026-06-09T12:38:21+00:00", "published_display": "09 Jun 2026 12:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cartesian Therapeutics (RNAC) Shares Surge 30% on Licensing Agre", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxOcjlVb2UzVHlRb1pwbExRUWR3NC1KUkh4U3FkbXdOWk16eHRqbkRaNlNtWWxVZG9qc19iUnM4VzhhOUlZb29LZlhub0dBX252NVdCN1E1eTh5YllGSTJUbk5oaG5QeG9qRW14dHdhZi1JbjROQlQ4aFlaUmhjcnhDdUh4SERHZmk3TWFFYlJZRFFPY2hPOUppWWQtT0NoZ3BWZC1ucjlkSnBCU29QbW13Y25pRF9pMVZl?oc=5", "source_name": "GuruFocus", "published_at": "2026-06-09T07:00:00+00:00", "published_display": "09 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Is Cartesian Therapeutics Stock Trading Higher Today? - Cartesian Therapeutics (NASDAQ:RNAC)", "summary": "", "url": "https://news.google.com/rss/articles/CBMi4AFBVV95cUxPZnhTNVNXQnUzcElsNC15LVA3b2dGUXFNMmpYNm41RFZYVTVUQkNMa09WYlRXNDFqcm9Kc0RROS1rc29rMmx0VjRJbmszdXNwVzI2RWV3UUxDT3hXTEl6Q3NaNTdnVTQ3aXdpcFluWmFqVVJMYTR6RDBaZjVHQWVBT2NsNmVRM3lzaWpVbkdjcVhMdmI0V0tHaDdJUFBLcUxQQW1DOE9YNlNlUVJLekpGd1daVUpYSGpIX3pUeDBtaUVLUTNRVVZKTXdwMkNHdmFrY1FpdGl4YlE2MTh6SXkxMA?oc=5", "source_name": "Benzinga", "published_at": "2026-06-09T07:00:00+00:00", "published_display": "09 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cartesian Therapeutics Announces Strategic Licensing Agreement with WestGene Biopharma to Accelerate the Development of In Vivo CAR-T Platform in Autoimmune Diseases", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2AJBVV95cUxNemQ0MG1ZYWZCZDBkUzVwcTk1RWpOT3Y3dC1GMGlPY2trOWRCTWZXT1k5SVd3VlBpaDBlV1NhbVhOaHZxcmZhVWNsQWtOQWxpTGpBVnZiTjhkZ0VSMlZnN0F1N3F5YkdCdUQ1cU9sWU5nZTBuOWQxR21vMmlhMHh6TTVlX2lQa1JpV1NQS2J4U18wSjN5QnhzVUVhWmdpbUZ3WTJnU29CSTh4MFhIazdzQzUzZTdHcktTTzJDQWxtbG9ReDdSQ2lIQ3FsaW1kVU9nNnI2UzV5TlVLblRUNW9LVWlJM2RYNU1LVG8wNFlVOUZpUmpKdm5kdDJ0aVdKeDBGMlJTV21ldUM0ZDQ4WHlBa3RWZkUyV2VNN1pzb2liMWFHZGlucVVCaUg0TERzT3pZM0RQeTdOUFo1ZkVKWWYxeGJZZVI0Rl9uVHlyV091WFVaNDI4RGlpNg?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-06-09T07:00:00+00:00", "published_display": "09 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cartesian inks licensing deal with WestGene (RNAC:NASDAQ)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiggFBVV95cUxPQ3ZPMjdYY18xMENkSEI4aU5CNGxGOWctRmF3SERUM1hueko5VFBZYjE5UnI0MWVNVGZwQzZtSGZxSElpalpmU3FoUXpuM2l1a2FFQTNNaFFwRUlObGpONkxKV0RvZWJ4OGU5WEZiVWNGRjZDV3ZEV3owcXZuZUNsNW5B?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-06-09T07:00:00+00:00", "published_display": "09 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cartesian Therapeutics Secures Up to $150 Million Credit Facility From K2 HealthVentures", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/cartesian-therapeutics-secures-150-million-115253652.html", "source_name": "MT Newswires", "published_at": "2026-05-26T11:52:53+00:00", "published_display": "26 May 2026 11:52", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "We Think Cartesian Therapeutics (NASDAQ:RNAC) Needs To Drive Business Growth Carefully", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-17T07:00:00+00:00", "published_display": "17 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "We're Keeping An Eye On Cartesian Therapeutics' (NASDAQ:RNAC) Cash Burn Rate", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxOTkRDSi1oVmlTeDdZdDdkb2JVbkgzNHNseTNVLUIxM3d0MVlnalRmemVJMDBLd2h6Q0NoUG12Vmk4YnZuZUFUelVQa3RVUUltejlRSmdYMDBwVTRuWEN5cU9uaUM3UWl6cnVWRHhyQ1FWWjA3NnZrbVgtcjBsQ05FdVFHQWhQWlRXRFJ2NHM1SlphRjYtbHZQZ004SEVFQWdMTms2SUZJZw?oc=5", "source_name": "Market source", "published_at": "2026-05-17T07:00:00+00:00", "published_display": "17 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Five new Cartesian hires get stock options priced at $6.22", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxQWVlObjJjQW1NRkhydVBhWEl3Zkl2YnpzMUpZWTU1VWJWbHJoZ1p0X0xMZUhSZnFMckJsNXl2Y0FQQ2lKN0RmZzFON0xWVGJTNEpUVWgyNDJZRUEyUmJoaUpEMU9XSU4tMUhRQjF2Z2FKLXplYzRuTmdYcTN4SzMyS2xKdUZCYk1xWGwyQWNyclJTNmlGOXU2WE1INE9zX1pWV2RVTVhUaUQ4UE84QXdEb1NmWQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-04T07:00:00+00:00", "published_display": "04 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Cartesian Therapeutics: A Phase 3 mRNA CAR-T Bet", "summary": "", "url": "https://news.google.com/rss/articles/CBMikgFBVV95cUxPcUV0Y1dmZGpuME1rNVVMaFRqOHhvTVBrWlNCbVV6cTNIZ09ta25YVUFOeTRXTDl1cU9OaFhpNXVfVTkyU2oybjlEQmgwU2RzZjhjOTc3UTJqU3BtOHZCVW5qNWQwY2JsN1VGSUwwMnU3MEd5VWNHUDlNNXFFdWF5akJxMHQxbUg2NzgtZWs4bUhLZw?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-04-23T07:00:00+00:00", "published_display": "23 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Insiders' US$1.73m Investments In Red Following Cartesian Therapeutics' US$29m Dip In Market Value", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-03-25T07:00:00+00:00", "published_display": "25 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here's Why We're Watching Cartesian Therapeutics' (NASDAQ:RNAC) Cash Burn Situation", "summary": "", "url": "https://news.google.com/rss/articles/CBMihgFBVV95cUxNVllhV0dkQmtNV09jNV9hMC1uTmdSUXljY2FOMXNBNlA0ai0zb295WXN2cjVFR2Ywem1iQWRkX0hTbjg4cTdHMHdieFpOdmFuMGxWZFYyY2lLaEJCRXMyV0E3S0FpYTNVaUxxYTIwSVN0bUF0Ymg0cGNIa3NQcHBpd3JrRG1Ydw?oc=5", "source_name": "Market source", "published_at": "2025-12-05T08:00:00+00:00", "published_display": "05 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cartesian (RNAC) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiU0FVX3lxTFBHUFNsUG9zczNNRVE0ZDEybV9JR0RmTzVfYzQ5YUF4OHlnaC1tU3BqblNEQ3otUWl3LXBTdHMtU0JtOFBXbnZEQnZtdGdFNHBINHpR?oc=5", "source_name": "Stock Titan", "published_at": "2025-04-25T00:09:38+00:00", "published_display": "25 Apr 2025 00:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cartesian Therapeutics (RNAC) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTE5pRmtvdDl5OXQyUHBhM01rbjFlaHlZdGZnZkdrYlpxcjlEZkozek1WTXJ4WVltWGVqUHVBdFVnUmV4UHptSUZJX2pxcThXaENXZ2tOX3hSNUw2QQ?oc=5", "source_name": "MarketBeat", "published_at": "2023-11-18T17:14:26+00:00", "published_display": "18 Nov 2023 17:14", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Selecta Biosciences Announces Merger with Cartesian Therapeutics", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0gFBVV95cUxQdFo0ZlRHSW1nSmZGRTdyNHl0dVpjcm1vb3lQRy1xN29ZVFF5SDlKdlVSQ1pFOXljWEJSbmZhYXFIaVlNNXJIeUNZblhRcXl3MkczbG1pOFB4UXpna25EWDFoemdURHAtZ05xN2JIMjhlU3FoMVI2Y29vcnlrakhmVHRLMzZuMGxyVUJpMHdvS1c2em0yNUVyUGdTVnFrcXpsOVI2MGdmX1R1OGhzaDBOLXdBeXUyMldocFdEWk55ZlNodXBkbkZSSDlRYWtfYmJlVVE?oc=5", "source_name": "GlobeNewswire", "published_at": "2023-11-13T08:00:00+00:00", "published_display": "13 Nov 2023 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Enterprise value to EBITDA forward of Cartesian Therapeutics, Inc. \u2013 NASDAQ:RNAC", "summary": "This article displays financial data for Cartesian Therapeutics, Inc. (NASDAQ: RNAC), focusing on its enterprise value to EBITDA forward metric. The content appears to be a financial data snippet from TradingView, indicating no current trades and providing links to various financ", "url": "https://www.tradingview.com/symbols/NASDAQ-RNAC/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-07-14T22:43:58", "published_display": "14 Jul 2026 22:43", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cartesian Therapeutics Inc (RNAC)", "summary": "This article provides key financial data for Cartesian Therapeutics Inc (RNAC), a biotechnology and medical research company listed on the Nasdaq Stock Market. It summarizes its stock price, daily and 52-week ranges, market capitalization, outstanding shares, and earnings per sha", "url": "https://www.msn.com/en-ph/money/stockdetails/rnac-us-stock/fi-a22roc?ocid=winp2fpent", "source_name": "MSN", "published_at": "2026-07-12T22:40:49", "published_display": "12 Jul 2026 22:40", "sentiment": "negative", "sentiment_pct": 39, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Kyverna Therapeutics Sinks 13%: Here\u2019s Why", "summary": "", "url": "https://finance.yahoo.com/m/57b629c0-9b57-300d-bab5-69e9c31cc364/kyverna-therapeutics-sinks.html", "source_name": "24/7 Wall St.", "published_at": "2026-07-10T19:59:59+00:00", "published_display": "10 Jul 2026 19:59", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cartesian Therapeutics : RNAC", "summary": "", "url": "https://news.google.com/rss/articles/CBMiTkFVX3lxTE9xSTBIdDZCV21zaHJwRVE5Q0xkS3dEcUY1R2NocGsyN1JjRF8zazMySW9iams2TktuLUtSTWUxMmZFTGR2Z1gzNnBudm5Bdw?oc=5", "source_name": "24/7 Wall St.", "published_at": "2026-07-10T19:59:59+00:00", "published_display": "10 Jul 2026 19:59", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cartesian Therapeutics Inc. : RNAC", "summary": "This article provides details on Cartesian Therapeutics Inc. (RNAC), a clinical-stage biopharmaceutical company focusing on nanoparticle immunomodulatory drugs. It lists the company's stock data, including its NASDAQ exchange, USD currency, and its classification within the healt", "url": "https://247wallst.com/companies/rnac/", "source_name": "24/7 Wall St.", "published_at": "2026-07-10T20:41:03", "published_display": "10 Jul 2026 20:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "macro", "event_label": "Macro sensitivity", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Emerging Therapies Transforming the Myasthenia Gravis Market by DelveInsight | Sanofi, Cartesian Therapeutics, Takeda, UCB Biopharma, Roche, Janssen R&D, Immunovant Sciences GmbH, Argenx-Halozyme", "summary": "The Myasthenia Gravis market is projected to grow significantly from approximately USD 6 billion in 2025 to nearly USD 16 billion by 2036, driven by new therapies and increased awareness. Recent FDA approvals for treatments like Vyvgart and UPLIZNA have expanded options for patie", "url": "https://www.barchart.com/story/news/3203735/emerging-therapies-transforming-the-myasthenia-gravis-market-by-delveinsight-sanofi-cartesian-therapeutics-takeda-ucb-biopharma-roche-janssen-rd-immunovant-sciences-gmbh-argenxhalozyme", "source_name": "Barchart.com", "published_at": "2026-07-10T08:40:08", "published_display": "10 Jul 2026 08:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wedbush Initiates Coverage of Cartesian Therapeutics (RNAC) with Outperform Recommendation", "summary": "Wedbush has initiated coverage of Cartesian Therapeutics (RNAC) with an Outperform recommendation. This indicates a positive outlook from the analyst firm regarding the company's stock performance. Investors will likely watch for further developments and market reactions to this ", "url": "https://www.msn.com/en-us/technology/biotechnology/wedbush-initiates-coverage-of-cartesian-therapeutics-rnac-with-outperform-recommendation/ar-AA1IhBOf?apiversion=v2&domshim=1&noservercache=1&noservertelemetry=1&batchservertelemetry=1&renderwebcomponents=1&wcseo=1", "source_name": "MSN", "published_at": "2026-07-04T20:09:26", "published_display": "04 Jul 2026 20:09", "sentiment": "positive", "sentiment_pct": 75, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cartesian Therapeutics Announces New Employment Inducement Grants", "summary": "Cartesian Therapeutics, Inc. has granted inducement awards to eight new employees, issuing options to purchase a total of 238,700 shares of common stock at an exercise price of $10.18. These options, vesting over four years, were granted on July 1, 2026, under the Company\u2019s Amend", "url": "https://www.manilatimes.net/2026/07/02/tmt-newswire/globenewswire/cartesian-therapeutics-announces-new-employment-inducement-grants/2377429", "source_name": "The Manila Times", "published_at": "2026-07-03T06:38:49", "published_display": "03 Jul 2026 06:38", "sentiment": "positive", "sentiment_pct": 64, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cartesian offers 8 new hires stock options worth 238,700 shares", "summary": "Cartesian Therapeutics (NASDAQ: RNAC) granted inducement stock options for 238,700 common shares to eight new employees, effective July 1, 2026. The options have an exercise price of $10.18 and will vest 25% on July 1, 2027, with the remainder vesting monthly until July 1, 2030. ", "url": "https://www.stocktitan.net/news/RNAC/cartesian-therapeutics-announces-new-employment-inducement-gfg7sovh36xa.html", "source_name": "Stock Titan", "published_at": "2026-07-02T10:41:06", "published_display": "02 Jul 2026 10:41", "sentiment": "positive", "sentiment_pct": 63, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RNAC - Cartesian Therapeutics Inc Latest SEC Filings", "summary": "This article provides the latest SEC filing information for Cartesian Therapeutics Inc. (RNAC), including its last closing price, financial overview, stock performance metrics, insider and institutional ownership, and profitability ratios. It details various financial statistics ", "url": "https://finviz.com/stock?t=RNAC&b=2&p=d&ty=lf", "source_name": "Finviz", "published_at": "2026-06-30T05:10:00", "published_display": "30 Jun 2026 05:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Cartesian Therapeutics, Inc. \u2013 NASDAQ:RNAC", "summary": "This article provides the enterprise value to EBIT forward for Cartesian Therapeutics, Inc. (NASDAQ: RNAC). It appears to be a financial data snippet from TradingView, focusing on key financial metrics for the biotechnology company. The content primarily lists navigation and site", "url": "https://www.tradingview.com/symbols/NASDAQ-RNAC/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T06:40:41", "published_display": "28 Jun 2026 06:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Cartesian Therapeutics, Inc. \u2013 GETTEX:1S70", "summary": "The article provides financial information for Cartesian Therapeutics, Inc. (GETTEX:1S70), specifically focusing on its \"Price to book forward\" metric. It appears to be a financial data page from TradingView, showing that the market is closed with no trades.", "url": "https://www.tradingview.com/symbols/GETTEX-1S70/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T15:10:19", "published_display": "26 Jun 2026 15:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Cartesian Therapeutics, Inc. \u2013 NASDAQ:RNAC", "summary": "This article provides financial information for Cartesian Therapeutics, Inc. (NASDAQ: RNAC) focusing on its price-to-earnings forward metric. It appears to be a stub or an incomplete data listing from a financial platform like TradingView, with placeholders for specific values. T", "url": "https://www.tradingview.com/symbols/NASDAQ-RNAC/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T13:41:00", "published_display": "26 Jun 2026 13:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cartesian Therapeutics, Inc. Actuals & Estimates (NASDAQ:RNAC)", "summary": "This article provides an overview of Cartesian Therapeutics, Inc. (NASDAQ: RNAC) stock, including its current price, historical highs and lows, market capitalization, and analyst forecasts. It details financial actuals and estimates for income, balance, and cash flow statements, ", "url": "https://www.tradingview.com/symbols/NASDAQ-RNAC/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T08:09:58", "published_display": "26 Jun 2026 08:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cartesian Therapeutics, Inc. Actuals & Estimates (BOATS:RNAC)", "summary": "This article provides an overview of Cartesian Therapeutics, Inc. (RNAC) stock, including its financial actuals and estimates as traded on BOATS exchange. It covers analyst forecasts, historical price data, upcoming earnings reports, and key financial metrics like revenue, net in", "url": "https://www.tradingview.com/symbols/BOATS-RNAC/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T06:41:00", "published_display": "26 Jun 2026 06:41", "sentiment": "negative", "sentiment_pct": 40, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Cartesian Therapeutics, Inc. \u2013 GETTEX:1S70", "summary": "This page provides financial information for Cartesian Therapeutics, Inc. under the ticker GETTEX:1S70, specifically focusing on its price-to-sales forward metric. The data is explicitly noted as \"Made by humans\" and the market status is closed with no trades.", "url": "https://www.tradingview.com/symbols/GETTEX-1S70/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-25T22:40:52", "published_display": "25 Jun 2026 22:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cartesian Therapeutics Inc (RNAC) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of Cartesian Therapeutics Inc (RNAC), detailing its current price momentum, support and resistance levels, and indicator readings. It highlights that the stock is trading between resistance at $12.06 and support at $7.03, suitable for ra", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-rnac/technical", "source_name": "TradingKey", "published_at": "2026-06-24T10:12:25", "published_display": "24 Jun 2026 10:12", "sentiment": "positive", "sentiment_pct": 64, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RNAC Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a stock forecast for Cartesian Therapeutics, Inc. (RNAC) including analyst price targets, current stock performance, and historical price data. It also details the company's financials, future earnings expectations, and market capitalization, offering insigh", "url": "https://www.tradingview.com/symbols/NASDAQ-RNAC/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-24T08:10:11", "published_display": "24 Jun 2026 08:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cartesian Therapeutics (Nasdaq:RNAC) - Stock Analysis", "summary": "Cartesian Therapeutics (Nasdaq:RNAC) is a clinical-stage biotechnology company developing mRNA cell therapies for autoimmune diseases. The stock is currently trading significantly below its estimated fair value, but faces risks including negative shareholder equity, volatile shar", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rnac/cartesian-therapeutics", "source_name": "Simply Wall Street", "published_at": "2026-06-22T02:10:36", "published_display": "22 Jun 2026 02:10", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cartesian Therapeutics Shareholders Back Directors and Governance Measures", "summary": "Cartesian Therapeutics shareholders demonstrated strong support for the company's leadership and governance, electing three Class I directors and approving executive compensation. They also ratified Ernst & Young LLP as their independent public accounting firm for 2026, indicatin", "url": "https://www.theglobeandmail.com/investing/markets/stocks/RNAC/pressreleases/2546685/cartesian-therapeutics-shareholders-back-directors-and-governance-measures/", "source_name": "The Globe and Mail", "published_at": "2026-06-19T00:39:37", "published_display": "19 Jun 2026 00:39", "sentiment": "negative", "sentiment_pct": 40, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Shareholders of Cartesian Therapeutics (NASDAQ: RNAC) back board, pay and auditor", "summary": "Cartesian Therapeutics (NASDAQ: RNAC) shareholders held their 2026 Annual Meeting, with an 82.42% turnout. They elected three Class I directors to serve until the 2029 Annual Meeting, approved executive compensation on an advisory basis, and ratified Ernst & Young LLP as their in", "url": "https://www.stocktitan.net/sec-filings/RNAC/8-k-cartesian-therapeutics-inc-reports-material-event-c1847f5af63b.html", "source_name": "Stock Titan", "published_at": "2026-06-17T20:10:42", "published_display": "17 Jun 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cartesian Therapeutics Inc (RNAC) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article from TradingKey reports on Cartesian Therapeutics Inc (RNAC)'s stock performance, showing a 5% gain. However, it notes that relevant data regarding the company's revenue breakdown by business segments and regions has not yet been disclosed. The page primarily serves ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-rnac/revenue", "source_name": "TradingKey", "published_at": "2026-06-17T09:10:18", "published_display": "17 Jun 2026 09:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cartesian Therapeutics Inc (RNAC) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "This article provides an earnings forecast for Cartesian Therapeutics Inc (RNAC), detailing its current earnings forecast score, analyst ratings, and price targets. It highlights that the company's expected revenue for the next quarter is $134.75K and the average analyst price ta", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-rnac/earnings", "source_name": "TradingKey", "published_at": "2026-06-16T23:40:33", "published_display": "16 Jun 2026 23:40", "sentiment": "positive", "sentiment_pct": 63, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cartesian Therapeutics Inc PE Ratio (TTM) & PE Ratio (TTM) Charts - RNAC", "summary": "This article from GuruFocus.com provides a detailed financial overview of Cartesian Therapeutics Inc (RNAC), focusing on its Price-to-Earnings (PE) Ratio (TTM). It highlights that the company is currently operating at a loss, thus its TTM PE ratio is listed as \"At Loss.\" The arti", "url": "https://www.gurufocus.com/stock/US059K/data/pe-ratio", "source_name": "GuruFocus", "published_at": "2026-06-15T23:08:50", "published_display": "15 Jun 2026 23:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cartesian Therapeutics Announces In Vivo CAR-T Licensing Alliance", "summary": "Cartesian Therapeutics has formed a strategic licensing alliance with WestGene Biopharma to develop in vivo CAR-T therapies for autoimmune diseases. This collaboration will combine Cartesian\u2019s mRNA payloads with WestGene\u2019s lipid nanoparticle delivery platform, aiming to eliminate", "url": "https://www.theglobeandmail.com/investing/markets/stocks/RNAC/pressreleases/2397566/cartesian-therapeutics-announces-in-vivo-car-t-licensing-alliance/", "source_name": "The Globe and Mail", "published_at": "2026-06-13T12:10:48", "published_display": "13 Jun 2026 12:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cartesian Therapeutics Announces New Employment Inducement Grant", "summary": "Cartesian Therapeutics, Inc. (NASDAQ: RNAC) announced the granting of an inducement award to a new employee on June 8, 2026. The award includes an option to purchase 6,100 shares of common stock at an exercise price of $5.86, vesting over four years. This grant aligns with Nasdaq", "url": "https://www.globenewswire.com/news-release/2026/06/12/3311308/0/en/cartesian-therapeutics-announces-new-employment-inducement-grant.html", "source_name": "GlobeNewswire", "published_at": "2026-06-13T09:41:10", "published_display": "13 Jun 2026 09:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "New hire at Cartesian gets 6,100 stock options vesting to 2030", "summary": "Cartesian Therapeutics (NASDAQ: RNAC) has granted a new employee an inducement stock option for 6,100 shares at an exercise price of $5.86. The option vests through June 8, 2030, with 25% vesting after one year and the remainder in monthly installments, and has a ten-year term. T", "url": "https://www.stocktitan.net/news/RNAC/cartesian-therapeutics-announces-new-employment-inducement-exmhp6osmm4q.html", "source_name": "Stock Titan", "published_at": "2026-06-12T20:09:40", "published_display": "12 Jun 2026 20:09", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cartesian Therapeutics Signs Licensing Agreement With WestGene to Develop Therapies for Autoimmune Diseases", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/cartesian-therapeutics-signs-licensing-agreement-124226099.html", "source_name": "MT Newswires", "published_at": "2026-06-09T12:42:26+00:00", "published_display": "09 Jun 2026 12:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cartesian Therapeutics stock jumps on WestGene partnership deal By Investing.com", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxPNHY3SERkMHBsRk9wTTFnQlpnZHpqeE9FUVZoVVJQaUp2MFA5NWVxT2FZcWc5YzZqNHJwNFRZWXJFVm4xX1ZSOXBrNV9PckE4aFNiQjlZTWRPRnd4WllyT1JsanIzQm9TTnF2dkM1MUM0b3ozOWlFSXp0M1plZkFEM2l3NEx4ZVBVR0hPRVJtdDI5dHpOdXFYR081MktRZFlYUjFrU25mOVZwYUVpVHpnMFBhWnRjdEEzMEJ6N1NXVm9aZw?oc=5", "source_name": "Investing.com Nigeria", "published_at": "2026-06-09T12:38:21+00:00", "published_display": "09 Jun 2026 12:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cartesian Therapeutics (RNAC) Shares Surge 30% on Licensing Agre", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxOcjlVb2UzVHlRb1pwbExRUWR3NC1KUkh4U3FkbXdOWk16eHRqbkRaNlNtWWxVZG9qc19iUnM4VzhhOUlZb29LZlhub0dBX252NVdCN1E1eTh5YllGSTJUbk5oaG5QeG9qRW14dHdhZi1JbjROQlQ4aFlaUmhjcnhDdUh4SERHZmk3TWFFYlJZRFFPY2hPOUppWWQtT0NoZ3BWZC1ucjlkSnBCU29QbW13Y25pRF9pMVZl?oc=5", "source_name": "GuruFocus", "published_at": "2026-06-09T07:00:00+00:00", "published_display": "09 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Is Cartesian Therapeutics Stock Trading Higher Today? - Cartesian Therapeutics (NASDAQ:RNAC)", "summary": "", "url": "https://news.google.com/rss/articles/CBMi4AFBVV95cUxPZnhTNVNXQnUzcElsNC15LVA3b2dGUXFNMmpYNm41RFZYVTVUQkNMa09WYlRXNDFqcm9Kc0RROS1rc29rMmx0VjRJbmszdXNwVzI2RWV3UUxDT3hXTEl6Q3NaNTdnVTQ3aXdpcFluWmFqVVJMYTR6RDBaZjVHQWVBT2NsNmVRM3lzaWpVbkdjcVhMdmI0V0tHaDdJUFBLcUxQQW1DOE9YNlNlUVJLekpGd1daVUpYSGpIX3pUeDBtaUVLUTNRVVZKTXdwMkNHdmFrY1FpdGl4YlE2MTh6SXkxMA?oc=5", "source_name": "Benzinga", "published_at": "2026-06-09T07:00:00+00:00", "published_display": "09 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cartesian Therapeutics Announces Strategic Licensing Agreement with WestGene Biopharma to Accelerate the Development of In Vivo CAR-T Platform in Autoimmune Diseases", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2AJBVV95cUxNemQ0MG1ZYWZCZDBkUzVwcTk1RWpOT3Y3dC1GMGlPY2trOWRCTWZXT1k5SVd3VlBpaDBlV1NhbVhOaHZxcmZhVWNsQWtOQWxpTGpBVnZiTjhkZ0VSMlZnN0F1N3F5YkdCdUQ1cU9sWU5nZTBuOWQxR21vMmlhMHh6TTVlX2lQa1JpV1NQS2J4U18wSjN5QnhzVUVhWmdpbUZ3WTJnU29CSTh4MFhIazdzQzUzZTdHcktTTzJDQWxtbG9ReDdSQ2lIQ3FsaW1kVU9nNnI2UzV5TlVLblRUNW9LVWlJM2RYNU1LVG8wNFlVOUZpUmpKdm5kdDJ0aVdKeDBGMlJTV21ldUM0ZDQ4WHlBa3RWZkUyV2VNN1pzb2liMWFHZGlucVVCaUg0TERzT3pZM0RQeTdOUFo1ZkVKWWYxeGJZZVI0Rl9uVHlyV091WFVaNDI4RGlpNg?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-06-09T07:00:00+00:00", "published_display": "09 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cartesian inks licensing deal with WestGene (RNAC:NASDAQ)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiggFBVV95cUxPQ3ZPMjdYY18xMENkSEI4aU5CNGxGOWctRmF3SERUM1hueko5VFBZYjE5UnI0MWVNVGZwQzZtSGZxSElpalpmU3FoUXpuM2l1a2FFQTNNaFFwRUlObGpONkxKV0RvZWJ4OGU5WEZiVWNGRjZDV3ZEV3owcXZuZUNsNW5B?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-06-09T07:00:00+00:00", "published_display": "09 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cartesian Therapeutics Secures Up to $150 Million Credit Facility From K2 HealthVentures", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/cartesian-therapeutics-secures-150-million-115253652.html", "source_name": "MT Newswires", "published_at": "2026-05-26T11:52:53+00:00", "published_display": "26 May 2026 11:52", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "We Think Cartesian Therapeutics (NASDAQ:RNAC) Needs To Drive Business Growth Carefully", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-17T07:00:00+00:00", "published_display": "17 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "We're Keeping An Eye On Cartesian Therapeutics' (NASDAQ:RNAC) Cash Burn Rate", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxOTkRDSi1oVmlTeDdZdDdkb2JVbkgzNHNseTNVLUIxM3d0MVlnalRmemVJMDBLd2h6Q0NoUG12Vmk4YnZuZUFUelVQa3RVUUltejlRSmdYMDBwVTRuWEN5cU9uaUM3UWl6cnVWRHhyQ1FWWjA3NnZrbVgtcjBsQ05FdVFHQWhQWlRXRFJ2NHM1SlphRjYtbHZQZ004SEVFQWdMTms2SUZJZw?oc=5", "source_name": "Market source", "published_at": "2026-05-17T07:00:00+00:00", "published_display": "17 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Five new Cartesian hires get stock options priced at $6.22", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxQWVlObjJjQW1NRkhydVBhWEl3Zkl2YnpzMUpZWTU1VWJWbHJoZ1p0X0xMZUhSZnFMckJsNXl2Y0FQQ2lKN0RmZzFON0xWVGJTNEpUVWgyNDJZRUEyUmJoaUpEMU9XSU4tMUhRQjF2Z2FKLXplYzRuTmdYcTN4SzMyS2xKdUZCYk1xWGwyQWNyclJTNmlGOXU2WE1INE9zX1pWV2RVTVhUaUQ4UE84QXdEb1NmWQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-04T07:00:00+00:00", "published_display": "04 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cartesian Therapeutics: A Phase 3 mRNA CAR-T Bet", "summary": "", "url": "https://news.google.com/rss/articles/CBMikgFBVV95cUxPcUV0Y1dmZGpuME1rNVVMaFRqOHhvTVBrWlNCbVV6cTNIZ09ta25YVUFOeTRXTDl1cU9OaFhpNXVfVTkyU2oybjlEQmgwU2RzZjhjOTc3UTJqU3BtOHZCVW5qNWQwY2JsN1VGSUwwMnU3MEd5VWNHUDlNNXFFdWF5akJxMHQxbUg2NzgtZWs4bUhLZw?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-04-23T07:00:00+00:00", "published_display": "23 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insiders' US$1.73m Investments In Red Following Cartesian Therapeutics' US$29m Dip In Market Value", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-03-25T07:00:00+00:00", "published_display": "25 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here's Why We're Watching Cartesian Therapeutics' (NASDAQ:RNAC) Cash Burn Situation", "summary": "", "url": "https://news.google.com/rss/articles/CBMihgFBVV95cUxNVllhV0dkQmtNV09jNV9hMC1uTmdSUXljY2FOMXNBNlA0ai0zb295WXN2cjVFR2Ywem1iQWRkX0hTbjg4cTdHMHdieFpOdmFuMGxWZFYyY2lLaEJCRXMyV0E3S0FpYTNVaUxxYTIwSVN0bUF0Ymg0cGNIa3NQcHBpd3JrRG1Ydw?oc=5", "source_name": "Market source", "published_at": "2025-12-05T08:00:00+00:00", "published_display": "05 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cartesian (RNAC) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiU0FVX3lxTFBHUFNsUG9zczNNRVE0ZDEybV9JR0RmTzVfYzQ5YUF4OHlnaC1tU3BqblNEQ3otUWl3LXBTdHMtU0JtOFBXbnZEQnZtdGdFNHBINHpR?oc=5", "source_name": "Stock Titan", "published_at": "2025-04-25T00:09:38+00:00", "published_display": "25 Apr 2025 00:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cartesian Therapeutics (RNAC) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTE5pRmtvdDl5OXQyUHBhM01rbjFlaHlZdGZnZkdrYlpxcjlEZkozek1WTXJ4WVltWGVqUHVBdFVnUmV4UHptSUZJX2pxcThXaENXZ2tOX3hSNUw2QQ?oc=5", "source_name": "MarketBeat", "published_at": "2023-11-18T17:14:26+00:00", "published_display": "18 Nov 2023 17:14", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Selecta Biosciences Announces Merger with Cartesian Therapeutics", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0gFBVV95cUxQdFo0ZlRHSW1nSmZGRTdyNHl0dVpjcm1vb3lQRy1xN29ZVFF5SDlKdlVSQ1pFOXljWEJSbmZhYXFIaVlNNXJIeUNZblhRcXl3MkczbG1pOFB4UXpna25EWDFoemdURHAtZ05xN2JIMjhlU3FoMVI2Y29vcnlrakhmVHRLMzZuMGxyVUJpMHdvS1c2em0yNUVyUGdTVnFrcXpsOVI2MGdmX1R1OGhzaDBOLXdBeXUyMldocFdEWk55ZlNodXBkbkZSSDlRYWtfYmJlVVE?oc=5", "source_name": "GlobeNewswire", "published_at": "2023-11-13T08:00:00+00:00", "published_display": "13 Nov 2023 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 90, "total_relevant": 51, "sentiment_summary": {"positive": 11, "negative": 4, "neutral": 36, "score": 53, "total": 51, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 80, "events": [{"event": "general", "label": "Market update", "weight": 15.75, "count": 28}, {"event": "earnings", "label": "Earnings", "weight": 6.05, "count": 13}, {"event": "deals", "label": "Deals and strategy", "weight": 2.0, "count": 3}, {"event": "analyst", "label": "Analyst action", "weight": 1.65, "count": 3}, {"event": "liquidity", "label": "Balance sheet", "weight": 1.65, "count": 3}, {"event": "macro", "label": "Macro sensitivity", "weight": 0.55, "count": 1}], "positive_events": 11, "negative_events": 4}, "market_context": {"has_market_context": true, "latest_close": 9.46, "latest_week": "2026-07-10", "one_week_move": -10.7, "four_week_move": -0.5, "twelve_week_move": 34.4, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": 1.261214, "market_dynamics_buy_signal": false, "relative_strength": -3.251446, "fair_value_gap": -44.1, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "undecided", "expectation_probability": 47.2769, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-10.7% over one week, -0.5% over four weeks, trend active, and below fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "negative", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 62, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "TradingView", "count": 9}, {"label": "Market source", "count": 7}, {"label": "Stock Titan", "count": 5}, {"label": "simplywall.st", "count": 4}, {"label": "24/7 Wall St.", "count": 3}, {"label": "TradingKey", "count": 3}, {"label": "GlobeNewswire", "count": 3}, {"label": "MSN", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 43}, {"label": "Industry context", "count": 8}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 28}, {"label": "Earnings", "count": 13}, {"label": "Analyst action", "count": 3}, {"label": "Deals and strategy", "count": 3}, {"label": "Balance sheet", "count": 3}, {"label": "Macro sensitivity", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "53/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "negative", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "80/100 classification confidence."}, {"label": "Company focus", "value": "43", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "2", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "-10.7% over one week, -0.5% over four weeks, trend active, and below fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Enterprise value to EBITDA forward of Cartesian Therapeutics, Inc. \u2013 NASDAQ:RNAC"}], "updated_at": "2026-07-16T10:34:45.889866+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}